Literature DB >> 30283254

Hormonal Contraception and Breast Cancer Risk.

Nicole D White1.   

Abstract

Contemporary hormonal contraception formulations contain lower doses of estrogen, have new synthetic progestin components, and provide novel methods of delivery that have not been studied extensively in relation to breast cancer risk. Given that hormonal contraception is the leading method of birth control in the United States, it is important to reevaluate risk using current formulations. Recent studies including contemporary hormonal contraception formulations will be described.

Entities:  

Keywords:  birth control; breast cancer; contraception; estrogen; hormones

Year:  2018        PMID： 30283254      PMCID： PMC6124967          DOI： 10.1177/1559827618754833

Source DB:  PubMed          Journal:  Am J Lifestyle Med        ISSN： 1559-8276


  7 in total

1.  Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies.

Authors: 
Journal:  Lancet       Date:  1996-06-22       Impact factor: 79.321

2.  Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995.

Authors:  Jo Jones; William Mosher; Kimberly Daniels
Journal:  Natl Health Stat Report       Date:  2012-10-18

3.  Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age.

Authors:  Elisabeth F Beaber; Diana S M Buist; William E Barlow; Kathleen E Malone; Susan D Reed; Christopher I Li
Journal:  Cancer Res       Date:  2014-08-01       Impact factor: 12.701

4.  Current Contraceptive Use and Variation by Selected Characteristics Among Women Aged 15-44: United States, 2011-2013.

Authors:  Kimberly Daniels; Jill Daugherty; Jo Jones; William Mosher
Journal:  Natl Health Stat Report       Date:  2015-11-10

5.  Oral contraceptives cause evolutionarily novel increases in hormone exposure: A risk factor for breast cancer.

Authors:  Jennie L Lovett; Margo A Chima; Juliana K Wexler; Kendall J Arslanian; Andrea B Friedman; Chantal B Yousif; Beverly I Strassmann
Journal:  Evol Med Public Health       Date:  2017-06-05

6.  Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study.

Authors:  Lisa Iversen; Selvaraj Sivasubramaniam; Amanda J Lee; Shona Fielding; Philip C Hannaford
Journal:  Am J Obstet Gynecol       Date:  2017-02-08       Impact factor: 8.661

7.  Contemporary Hormonal Contraception and the Risk of Breast Cancer.

Authors:  Lina S Mørch; Charlotte W Skovlund; Philip C Hannaford; Lisa Iversen; Shona Fielding; Øjvind Lidegaard
Journal:  N Engl J Med       Date:  2017-12-07       Impact factor: 91.245
  7 in total
  3 in total

Review 1.  Proteomics and its applications in breast cancer.

Authors:  Anca-Narcisa Neagu; Danielle Whitham; Emma Buonanno; Avalon Jenkins; Teodora Alexa-Stratulat; Bogdan Ionel Tamba; Costel C Darie
Journal:  Am J Cancer Res       Date:  2021-09-15       Impact factor: 5.942

Review 2.  Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures.

Authors:  Dharambir Kashyap; Deeksha Pal; Riya Sharma; Vivek Kumar Garg; Neelam Goel; Deepika Koundal; Atef Zaguia; Shubham Koundal; Assaye Belay
Journal:  Biomed Res Int       Date:  2022-04-18       Impact factor: 3.246

3.  National and Subnational Incidence, Mortality, and Years of Life Lost Due to Breast Cancer in Iran: Trends and Age-Period-Cohort Analysis Since 1990.

Authors:  Bahar Ataeinia; Sahar Saeedi Moghaddam; Mahsima Shabani; Kimiya Gohari; Ali Sheidaei; Nazila Rezaei; Shohreh Naderimagham; Erfan Ghasemi; Mahtab Rouhifard Khalilabad; Shahin Roshani; Yosef Farzi; Farshad Farzadfar
Journal:  Front Oncol       Date:  2021-03-25       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.